Welcome to our dedicated page for Waldencast plc SEC filings (Ticker: WALD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Waldencast plc (NASDAQ: WALD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Waldencast files with the U.S. Securities and Exchange Commission primarily on Form 20-F for its annual report and Form 6-K for interim updates, transaction details, and other material information.
Recent Form 6-K filings referenced by the company include current reports furnishing quarterly and half-year financial results, such as operating results for specific quarters and six-month periods, along with trading updates. One Form 6-K includes Waldencast’s unaudited interim consolidated financial statements for the six months ended June 30, 2025 as an exhibit, while another furnishes a press release detailing Q2 2025 results and a Q3 2025 trading update.
Waldencast also uses Form 6-K to disclose material agreements and corporate actions. Examples include a credit agreement with lenders associated with the Lumina Capital Management group and agreements related to the sale and coexistence of the “Obagi” trademark in Japan with Rohto Pharmaceutical Co., Ltd. These documents, referenced as exhibits to Form 6-K, outline key terms of financing and trademark transactions that the company associates with its efforts to strengthen its balance sheet and refine its brand portfolio.
Through its SEC filings, Waldencast provides segment-level information for Obagi Medical and Milk Makeup, along with definitions and reconciliations for non-GAAP measures such as adjusted gross profit and adjusted EBITDA. Filings also describe the company’s ongoing strategic review of alternatives, its risk factors by reference to its Form 20-F, and the incorporation of certain 6-K reports into existing registration statements.
On Stock Titan, these filings can be viewed alongside AI-powered summaries that clarify the main points of each report, highlight segment performance, and point out notable items such as new credit facilities, trademark transactions, or updates on the strategic review. Users can follow new Form 6-K submissions in real time to monitor how Waldencast communicates financial results, capital structure changes, and other regulatory disclosures.
Waldencast plc Chief Executive Officer Michel Brousset has filed an initial statement of holdings, detailing his equity position in the company. He directly holds stock options over 4,135,340 Class A ordinary shares at an exercise price of $3.98 per share, vesting in three equal annual tranches through 2028. He also holds 264,294 restricted stock units, part of a 396,440‑unit grant made on October 30, 2024, scheduled to vest in three installments from 2025 to 2027. In addition, he owns 952,865 Class A ordinary shares directly. Indirectly, through Waldencast Ventures LP, he is associated with 2,848,334 Class A ordinary shares and 2,311,113 shares issuable upon exercise of private placement and working capital loan warrants. Waldencast Ventures LP is also party to arrangements requiring the future delivery of 1,424,161 Class A ordinary shares it holds to certain investors in exchange for their equity in Waldencast UK Limited.
Waldencast plc director Cristiano Souza has filed an initial statement of ownership showing substantial indirect and derivative stakes in the company. He is the controlling shareholder of Zeno Equity Partners LLP, which holds 12,252,580 Class A ordinary shares and warrants linked to 4,892,767 Class A shares at an exercise price of $11.5000 per share. Souza also has stock options tied to 712,083 Class A shares with a zero exercise price expiring on October 26, 2026, and a put option allowing him to exchange part of his equity interest in Waldencast UK Limited for 712,083 Class A shares held by Waldencast Ventures LP. He disclaims beneficial ownership of Zeno Equity Partners LLP’s holdings except to the extent of his pecuniary interest.
Waldencast plc director Thompson Motta Roberto Moses filed an initial ownership report showing his stake in the company’s Class A Ordinary Shares. The filing lists 18,727 shares held directly in his name and 100,000 shares held indirectly through Nexus Limited, which is controlled by his spouse.
The director disclaims beneficial ownership of the shares held by Nexus Limited, except to the extent of his pecuniary interest. This Form 3 does not report any new share purchases or sales; it establishes his existing ownership position as he becomes subject to insider reporting rules.
Waldencast plc director Aaron Chatterley filed an initial ownership report showing his equity stake in the company. He reports direct ownership of 57,453 Class A ordinary shares and restricted stock units tied to 18,727 underlying Class A ordinary shares at an exercise price of 0.0000 per share.
Footnotes state he was granted 56,180 restricted stock units on February 12, 2025, vesting in three tranches: 18,727 on February 12, 2025, 18,726 on October 28, 2025, and 18,727 on October 28, 2026. Each RSU represents a contingent right to receive one Class A ordinary share or an equivalent cash amount at the plan administrator's election.
Waldencast plc director Felipe Dutra has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The filing lists him as a director and does not report any share purchases, sales, or other transactions, making this a routine administrative disclosure of insider status.
Waldencast plc Chief Financial Officer Manfredi Manuel filed an initial statement of beneficial ownership. He directly holds 39,644 Class A ordinary shares and 79,289 restricted stock units representing the right to receive an equal number of Class A shares, subject to plan terms and vesting.
Waldencast plc director Juliette Hickman reported her equity holdings in the company. She directly holds 80,952 Class A ordinary shares and restricted stock units that are tied to 18,727 underlying Class A ordinary shares at an exercise price of $0.0000 per share.
A prior grant on February 12, 2025 covered 56,180 restricted stock units that vest in three tranches, with the final 18,727 units scheduled to vest on October 28, 2026. Each restricted stock unit corresponds to one Class A ordinary share or an equivalent cash amount.
Waldencast plc director and Chief Growth Officer Hind Sebti reported her equity holdings in the company. She holds 507,434 Class A ordinary shares directly, stock options covering 1,594,660 Class A ordinary shares at an exercise price of $3.9800 per share expiring on April 9, 2035, and 193,816 restricted stock units tied to Class A ordinary shares.
Footnotes state the options vest in three equal annual installments from January 1, 2026 through January 1, 2028, and that an earlier grant of 290,723 restricted stock units vests in three annual tranches from October 1, 2025 through October 1, 2027. Each RSU represents a right to receive one Class A ordinary share or cash of equivalent value.
Waldencast plc director Brookie Kelly has filed an initial ownership report showing a direct holding of 37,454 Class A Ordinary Shares. This Form 3 does not report any recent purchase or sale activity; it simply establishes Kelly’s current direct equity position in Waldencast.
Waldencast plc reported a difficult 2025, with heavy losses despite stable sales. Full-year net revenue was $272.1 million, down 0.7% from 2024, while Adjusted EBITDA fell to $16.1 million from $40.3 million. Net loss widened sharply to $248.1 million, driven mainly by goodwill impairments at Obagi Medical and Milk Makeup, higher financing costs and depreciation and amortization.
Q4 2025 net revenue was $72.0 million, flat year over year, but Adjusted EBITDA dropped to $6.6 million from $11.2 million as gross margins contracted and the company invested ahead of 2026 product launches, including Obagi injectables. Obagi Medical grew revenue 8.3% for the year, while Milk Makeup net revenue fell 11.4% amid softer international demand.
Waldencast worked to strengthen its balance sheet, selling the Obagi Japan trademark for $82.5 million and using $77.5 million to repay debt, and replacing its facility with a new $225 million three-year credit line. Net debt improved to $121.7 million as of December 31, 2025, from $154.2 million a year earlier, with cash rising to $30.4 million. The Board is running a broad strategic review and is not providing a 2026 outlook.